While the U.S. has historically led the global pharmaceutical industry by pursuing both continual innovation and high quality, those strengths could become areas of weakness in times of political uncertainty, according to PA Consulting expert Andy Prinz.
What’s it going to take for Australia’s biotech industry to be more self-sufficient? Although Australia is far away from the rest of the world, no one is an island when it comes to biotechnology, Ausbiotech CEO Lorraine Chiroiu said during the Ausbiotech 2023 conference held in Brisbane Nov. 1-3. Investors gathered to riff about what they were looking for in Australian biotech investments and what needs to change for the sector to be sustainable. All agreed that the science in Australia is top-notch but that the ecosystem needs more investment to be competitive.
Australia has a lot to celebrate when it comes to vaccines. The University of Queensland is where Ian Frazer invented the human papillomavirus vaccine Gardasil, and now Australia is projected to be the first in the word to eliminate cervical cancer, Queensland Deputy Premier Steven Miles said during the Ausbiotech 2023 conference held Nov. 1-3 in Brisbane, Australia.
What’s it going to take for Australia’s biotech industry to be more self-sufficient? Although Australia is far away from the rest of the world, no one is an island when it comes to biotechnology, Ausbiotech CEO Lorraine Chiroiu said during the Ausbiotech 2023 conference held in Brisbane Nov. 1-3. Investors gathered to riff about what they were looking for in Australian biotech investments and what needs to change for the sector to be sustainable. All agreed that the science in Australia is top-notch but that the ecosystem needs more investment to be competitive.
Australia has a lot to celebrate when it comes to vaccines. The University of Queensland is where Ian Frazer invented the human papillomavirus vaccine Gardasil, and now Australia is projected to be the first in the word to eliminate cervical cancer, Queensland Deputy Premier Steven Miles said during the Ausbiotech 2023 conference held Nov. 1-3 in Brisbane, Australia.
China is pushing to increase biopharma investment to woo foreign investors, and the State Council laid out policy areas to further incentivize foreign companies to expand their operations in the country. Among those policies are guaranteeing equal treatment of foreign-invested enterprises and domestic enterprises, particularly in government procurement activities.
China is pushing to increase biopharma investment to woo foreign investors, and the State Council laid out policy areas to further incentivize foreign companies to expand their operations in the country. Among those policies are guaranteeing equal treatment of foreign-invested enterprises and domestic enterprises, particularly in government procurement activities.
European biotechnology firms engaged in the discovery and development of new therapeutics collectively raised $1.9 billion in equity funding during the second quarter (Q2) of the year. Despite the ongoing lack of an IPO market – particularly for European firms – the total is roughly comparable with historic norms, absent the pandemic-related boom years of 2020 and 2021. It represents the fourth highest total raised during the last six years.
Swiss biotech firms raised CHF1.3 billion (US$1.5 billion) in equity and debt financing in 2022, a fall of 60% from the previous year’s total of over CHF3.3 billion. But it’s still ahead of historic pre-pandemic levels of funding.
Clinical trials in China are growing up in much the same way the R&D enterprise in China has grown up. They are evolving and becoming more sophisticated, reflecting the maturation of the R&D environment around them.
